The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Challenge in Treating Patients With Multiple Myeloma

Ajai Chari, MD
Published Online:4:17 PM, Thu December 6, 2018


Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the biggest challenge in treating patients with multiple myeloma.

The treatment landscape is very exciting, Chari says. Ten drugs have been approved over the last decade, while 4 of those were approved in 2015. However, the biggest challenge now with these patients is what happens when patients exhaust these options.

Patients who are penta-refractory are refractory to 5 of these currently approved therapies. The question is then what to do for these patients who have seemingly exhausted all options, Chari concludes.

At the 2018 ASH Annual Meeting, data from part 2 of the pivotal STORM trial demonstrated over a quarter of patients with penta-refractory multiple myeloma responded to the combination regimen of selinexor plus low-dose dexamethasone.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.